Dimerix Bioscience Pty Ltd   Report issue

For profit Phase 2 Phase 3
Founded: Victoria Australia (2004)
Status: Left NME R&D (2023)

Organization Overview

First Clinical Trial
2018
NCT03627715
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Dimerix Bioscience Pty Ltd | Renal Research

Active Ingredients

Drugs in Phase 3 Trials (1)

repagermanium (1 trial)

Drugs in Phase 2 Trials (1)

propagermanium (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Diabetic Nephropathies (Phase 2)

Glomerulosclerosis, Focal Segmental (Phase 2)

Kidney Diseases (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 3
  • # of Trial APIs: 2